P10 Prevalence of diabetes mellitus and impaired fasting blood glucose at the time of pancreatic cancer diagnosis, in a group of patients assisted at a gastroenterological reference center in Argentina

Abstract

Introduction: Diabetes mellitus (DM) is considered to be a risk factor for the development of pancreatic ductal adenocarcinoma (PDAC).

Objectives: Describe the prevalence of DM and of impaired fasting glucose (IFG) at the diagnosis of PDAC, among patients assisted in a gastroenterological reference center; Analyze differences in personal and nutritional characteristics in patients with both PDAC and DM; with both PDAC and IFG; and with PDAC but neither DM nor IFG; (3) Determine the time lapse between the diagnosis of DM and the diagnosis of PDAC.

Material and methods: Between October 2019 and March 2020, we analyzed 465 clinical records of PDAC-diagnosed patients over 18 years, from Oncology and Nutrition Sections.

Results: 171 clinical records (36.7 %) showed both PDAC and DM; 294 clinical records (63.2 %) showed PDAC but not DM. In 45.1% of the former, the interval between the diagnosis of DM and that of PDAC was <1 year, and in 17.65%, 15.69% and 21.57%, the lapses corresponded to 1 and 5 years, between 5 and 10 years y >10 years, respectively.

Conclusion: The prevalence of DM in PDAC patients (37 %) is higher than that .registered in the overall population (12.7 %), reaching a 45.10 % when detected during the first year of oncological diagnosis. Our results match the international literature relating recently-diagnosed DM with the presence of PDAC, as effect of shared risk factors between both diseases, or DM pathophysiology factors, or DM pharmacological therapeutic.